GlassScriptPhysician profile
William I Schwartz
NPI 1659479764
$23,477.90
in general payments reported to CMS, 2019-2025
54 companies · $1,861 in 2025
The $1,861 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,973 · 2020: $2,786 · 2021: $4,861 · 2022: $3,673 · 2023: $3,536 · 2024: $2,787 · 2025: $1,861.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,118 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,118.32 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,629.09 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $2,375.15 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,997.59 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Janssen Pharmaceuticals, INC | $1,799.48 | 2019-2025 | Spravato |
| Amarin Pharma, INC. | $1,298.58 | 2019-2023 | |
| Lilly USA, LLC | $1,194.94 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $1,157.47 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Corcept Therapeutics | $1,055.02 | 2021-2025 | Korlym |
| Amgen INC. | $1,031.49 | 2019-2024 | Otezla, Repatha |
| Allergan, INC. | $737.03 | 2019-2020 | |
| Pfizer INC. | $707.48 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $607.09 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $569.11 | 2022-2025 | Caplyta |
| Kowa Pharmaceuticals America, INC. | $436.92 | 2019-2024 | Zoryve |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $393.75 | 2019-2025 | Xifaxan |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Schwartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.